July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer
Apr 29, 2024, 14:18

Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer

Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn:

“An important question in the adjuvant treatment of high risk ER+/HER2 negative breast cancer with Abemacicib:

Is the benefit of Abemacicib compromised in those that require dose reductions?

A secondary analysis of MonarchE suggests that reducing the dose to manage side effects did not alter efficacy.

Clinicians should utilize dose modifications when necessary to maximize adherence.”

Matthew Goetz

Additional information.
Source: Matthew Goetz/LinkedIn